CTEV SHAREHOLDER ALERT: Investors Encouraged To Contact Kirby Mcinerney LLP About Potential Securities Laws Violations
[LEARN MORE ABOUT THE INVESTIGATION ]
What Happened?
On May 14, 2026, The Capitol Forum reported that the U.S. Department of Justice's anti-trust division has launched a criminal price-fixing investigation into Claritev. According to the article, officials are talking to third parties and investigating the Company's Data iSight pricing tool. On this news, the price of Claritev shares declined by $9.60 per share, or approximately 41%, from $23.47 per share on May 14, 2026 to close at $13.87 on May 15, 2026.
What Should I Do?
At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.
If you purchased or otherwise acquired Claritev securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at ..., or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]
Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
...

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment